Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Idorsia's gross profit for the
three
months ended in Mar. 2026 was CHF49.3 Mil. Idorsia's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was CHF192.6 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Idorsia's gross profit for the
three
months ended in Mar. 2026 was CHF49.3 Mil. Idorsia's Revenue for the
three
months ended in Mar. 2026 was CHF57.4 Mil. Therefore, Idorsia's Gross Margin % for the quarter that ended in Mar. 2026 was 85.95%.
Idorsia had a gross margin of 85.95% for the quarter that ended in Mar. 2026 => Durable competitive advantage
During the past 10 years, the highestGross Margin % of Idorsia was 95.31%. The lowest was 68.07%. And the median was 92.04%.
Idorsia (XSWX:IDIA) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Idorsia had a gross margin of 85.95% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Idorsia Gross Profit Related Terms
Idorsia Gross Profit Historical Data
* Premium members only.
The historical data trend for Idorsia's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:IDIA vs VRTX, REGN, ALNY: Gross Profit Comparison
For the Biotechnology subindustry, Idorsia's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's Gross Profit distribution charts can be found below:
* The bar in red indicates where Idorsia's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF192.6 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Idorsia (XSWX:IDIA) has a Gross Profit of CHF192.6 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Idorsia and its competitors.
Is Idorsia's Gross Profit too high?
Idorsia's current Gross Profit is CHF192.6 Mil. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Gross Profit compare to VRTX and REGN?
Idorsia's Gross Profit of CHF192.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Idorsia and its competitors. Idorsia's current Gross Profit is CHF192.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.90, compared to a current price of CHF6.17 — trading 112.6% above its estimated fair value. The current Gross Profit is CHF192.6 Mil. Idorsia's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current Gross Profit is CHF192.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF6.17 is trading 112.6% above its estimated GF Value™ of CHF2.90.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
Gross Profit: CHF192.6 Mil
GF Value™: CHF2.90 vs. price of CHF6.17 (112.6% above fair value)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score
Get the complete analysis for XSWX:IDIA
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
